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Abstract The 1000-fold induction of acute phase serum amyloid 
A (A-SAA) in the liver during inflammation indicates that this 
protein plays an important, though ill-defined, role in host de- 
fence. Paradoxically, prolonged overproduction of A-SAA is a 
causative factor in secondary amyloidosis and possibly other dis- 
eases uch as atherosclerosis; the ability to down-regulate A-SAA 
synthesis is therefore of considerable clinical importance. We 
have successfully generated anti-SAA hammerhead ribozymes 
and we report that they are capable of cleaving A-SAA mRNA 
in vitro. 
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1. Introduction 
The serum amyloid A (SAA) protein family is comprised of 
a number of differentially expressed polymorphic apolipopro- 
teins which are associated predominantly with HDL3 [1,2]. 
During the acute phase response a subset of the SAA's, the 
acute phase SAA's (A-SAA's), increase dramatically inconcen- 
tration [3]. There are two acute phase genes, A-SAA1 and 
A-SAA2, the products of which are 92% identical at the amino 
acid level. The association of A-SAA with HDL3 displaces 
apolipoprotein AI from the HDL particle and remodels it for 
an ill-defined short-term role in host defense [4,5]. However, in 
the long-term, high sustained levels of A-SAA may have detri- 
mental effects. The association of A-SAA with HDL3 may 
comprimise its capacity to mediate reverse cholesterol trans- 
port [6] and may contribute to the pathogenesis of atherosclero- 
sis in patients with chronic inflammatory diseases [7]. Also, the 
principal component of amyloid deposits formed during sec- 
ondary amyloidosis, a progressive fatal disease, is amyloid A, 
a proteolytic derivative of A-SAA [8], the generation of which 
appears to be dependent, at least in part, on the maintenance 
of high circulating levels of A-SAA. 
The capacity to down-regulate A-SAA synthesis is poten- 
tially of great benefit when the detrimental clinical conse- 
quences of prolonged over-production f A-SAA are consid- 
ered. There are several possible approaches to the therapeutic 
down-regulation f A-SAA, one of which is to interfere with 
the inductive pathway(s) of A-SAA biosynthesis mediated 
by inflammatory cytokines and hormones uch as interleu- 
kin-1 (IL-1), interleukin-6 (IL-6) and tumor necrosis factor-or 
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I'NF-~), and by glucocorticoids [9,10,11]. Reagents that in- 
hibit the action of cytokines, however, act non-specifically and 
could abrogate important and beneficial general immune func- 
tions if used over long periods of time. A more specific down- 
regulation could be achieved using antisense RNA or DNA 
molecules, which bind to the target mRNA and inhibit its 
translation. However, high levels of antisense RNA relative to 
target mRNA would likely be required and given the magnitude 
of A-SAA synthesis during inflammation this poses practical 
limitations. Hammerhead ribozymes (or RNA enzymes) are 
potentially a more effective alternative to antisense RNA in 
that, in addition to binding to the target RNA specifically, they 
cleave the RNA, dissociate, and participate infurther cleavages 
in a catalytic manner. Originally identified as cis-acting (self- 
cleaving) RNAs in plant viruses, they have subsequently been 
exploited for their ability to effect cleavage in trans [12]. So- 
called because they adopt a secondary structure that resembles 
a hammerhead on binding to the substrate, they can be de- 
signed to base-pair with their complementary target mRNA on 
either side of a GUX (X = A, C or U) triplet, and cleave the 
target immediately 3'to the triplet in a magnesium-dependent, 
protein-independent manner. In this paper we report the de- 
sign, synthesis and function of several hammerhead ribozymes 
that give specific and efficient cleavage of full-length A-SAA 
mRNA in vitro. 
2. Materials and methods 
2.1. Computer-assisted prediction of RNA secondary structure 
Prediction of A-SAA mRNA secondary structure was carried out by 
using the RNAPIotFold program (based on the algorithm of Zuker and 
Stiegler [13]) of the GCG package. 
2.2. Substrate mRNA 
Plasmid pGEMSAA, used as a template for A-SAA mRNA tran- 
scription, was generated as follows: A-SAA2 cDNA was PCR ampli- 
fied, gel-purified and cloned into the Apal and Nsil sites of pGEM 
5zf(+) (Promega, Madison, WI).The plasmid was linearized with Mscl 
(which cuts at the natural site of polyadenylation forA-SAA mRNA) 
prior to in vitro transcription. 
The A-SAA mRNA substrate was generated asfollows: a 555-base 
A-SAA mRNA product, comprising the entire 542 bases of the mature 
A-SAA2 mRNA and a 13-base 5" vector-derived lement, was tran- 
scribed as detailed below and gel-purified on a 4% polyacrylamide g l. 
The RNA band was eluted overnight in 2 volumes of RNA elution 
buffer (0.3 M sodium acetate, 0.2% SDS). The supernatant was phenol 
extracted once to remove residual SDS and the RNA was ethanol 
precipitated and redissolved in DEPC (diethylpyrocarbonate) treated 
dH20. 
2.3. Ribozyme plasmid construction 
Ribozyme sequences were synthesised as sense and antisense oligonu- 
cleotides using an Applied Biosystems 391 DNA synthesiser. The basic 
A-SAA ribozyme plasmid (RpSAA) was synthesised by annealing 
the oligonucleotides RBasF (5'-GAAAAGCTTGCCAAGGCTGA- 
TGAGTCCGTGAGGACGAAACGAAAAGTCTAGAGC-3') and 
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RBasR (5'-GCTCTAGACTTTTCGTTTCGTCCTCACGGACTCA- 
TCAGCCTTGGCAAGCTTTTC-3') which contain the restriction 
sites HindllI and Xbal. 
The autocatalytic ribozyme plasmid (RpSAA3') was synthesised by 
annealing the oligonucleotides Rib3'F (5'-ATTCTAGAGTCGACG- 
GACTCGAGTCCGTCCTGATGAGTCCGTGAGGACGAAACT- 
CTAGGGCCCTA-3') and Rib3'R (5'-TAGGGCCCTAGAGTTTC- 
GTCCTGACGGACTCATCAGGACGGACTCGAGTCCGTCGA- 
CTCTAGAAT-3') which contain the restriction sites XbaI and Apal. 
Sense and antisense oligonucleotide pairs were annealed by heating 
to 95°C for 3 min and cooling to room-temperature overnight, digested 
with appropriate restriction enzymes, and cloned into pcDNA 3 (In- 
vitrogen, Leek, The Netherlands). 
The sequences of all constructs were confirmed by dideoxy sequenc- 
ing using the Sequenase Version 2.0 kit (US Biochemical, Cleveland, 
OH). 
2.4. In vitro transcription of ribozyme and SAA mRNA 
Transcription of RNA's from plasmid templates that contained the 
T7 RNA polymerase promoter were carried out using the Ribomax 
transcription kit (Promega, Madison, WI). 
A typical 100/21 reaction mixture contained 5 pg linearised template 
DNA (see below), 80 mM HEPES-KC1, pH 7.5, 24 mM MgC12, 2 mM 
spermidine, 40 mM DTT, 5 mM rATP, rGTP and rCTP, 2 mM rUTP, 
120/2Ci [~-32p]UTP (specific activity 800 Ci/mmol) (Amersham, Bucks, 
UK), 3000 U T7 RNA polymerase and 0.15 U/pl RNAsin ribonuclease 
inhibitor (Boehringer Mannheim, Lewes, UK). 
The reactions were incubated at 37°C for 3~, h. Following transcrip- 
tion RNAse-free DNAse (Promega) was added at a concentration of
1 U/pg DNA template and incubated at 37°C for 15 min. This treat- 
ment was followed by phenol/chloroform extraction and ammonium 
acetate thanol precipitation of the RNA. 
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Fig. 1. Hammerhead ribozyme targetted against A-SAA mRNA. (a) A-SAA2 mRNA secondary structure predicted using the RNAPIotFold program; 
the GUU target site (residue 107-109) on an exposed loop is indicated on the left-hand side of the structure. (b) The hammerhead structure of RzSAA 
is formed from residues 101 116 on the A-SAA mRNA target and the catalytic strand containing the conserved bases of the ribozyme. The cleavage 
site immediately 3' to the GUU triplet (residues 107-109) is indicated. Note the U-rich content of the target sequence. 
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2.5. Ribozyme cleavage reactions 
Ribozyme and substrate were mixed and heated at 90°C in a solution 
of 50 mM Tris-HC1 and 5 15 mM MgC12 in the presence of 10 U 
RNAse inhibitor. The reactions were incubated at 37°C for various 
times. After incubation the reactions were stopped by adding an equal 
volume of stop solution (1 mM EDTA, pH 8.0, 0.25% bromophenol 
blue, 0.25% xylene cyanol in deionised formamide), heated at 95°C for 
3 min; products were size fractionated on a 5% polyacrylamide g l in 
TBE and autoradiographed. 
3. Results and discussion 
Hammerhead ribozymes can be designed to cleave virtually 
any mRNA since the only requirement for cleavage activity is 
the presence of a GUX triplet on the target mRNA. The A- 
SAA2 mRNA sequence was searched for potential GUX cleav- 
age sites and seven were identified. Several factors that increase 
the effectiveness of a ribozyme were taken into consideration 
when selecting the most suitable GUX target site for the anti- 
SAA ribozyme. These are: (a) the accessability of an mRNA 
target site for the ribozyme, (b) the strength of ribozyme- 
substrate base-pairing, and (c) the stability of the ribozyme. 
The most accessible target site on an mRNA substrate can 
in theory be identified using computer-generated predictions of 
mRNA secondary structures and previous ribozyme studies 
have established the importance ofusing such secondary struc- 
ture analyses in the selection of a ribozyme target site [14,15]. 
For example, Hullier et al. [15] used a predicted secondary 
structure of c~-lac mRNA when choosing an ct-lac ribozyme 
target site; two ribozymes targetted to an 'unstructured' region 
of ~-lac mRNA were much more effective in cultured cells than 
a ribozyme targetted to a central region predicted to have a 
complex secondary structure. We used the RNAPlotFold pro- 
gram (GCG) to predict he A-SAA2 mRNA secondary struc- 
ture and identified a GUU triplet (nucleotides 107 109) in an 
open-loop region (Fig. l a) which should be very accessable to 
a ribozyme in vivo. 
The length of the region flanking the target site determines 
the specificity of a ribozyme; however strong interactions be- 
tween a ribozyme and substrate mRNA can prevent rapid dis- 
sociation of the ribozyme following cleavage of the target [16]. 
This could significantly reduce the catalytic activity of the ri- 
bozyme. In theory a ribozyme will cleave with an optimal 
KcauKm an RNA that is base-paired with a free-energy of less 
than -16 kcal/mol [17]. Calculations have shown that a GC-rich 
ribozyme reaches a AG of <-16 with only 8 base-pairs. An 
AU-rich ribozyme is therefore more desirable than a GC-rich 
ribozyme in order to have the longest possible RNA binding 
sequence (and hence highest specificity) while maintaining ziG 
<-16. An A-rich ribozyme also eliminates the problem of wob- 
ble UG pairing between the ribozyme and target mRNA and 
consequently further increases the specificity of the ribozyme. 
As well as being in a relatively unstructured region of the 
A-SAA mRNA, the region surrounding the GUU triplet at 
bases 107-109 is very U-rich; thus this site was chosen as the 
target site around which an anti-SAA ribozyme was designed. 
The anti-A-SAA hammerhead ribozyme designed to cleave 
A-SAA mRNA was modelled on the design of Haselhoff and 
Gerlach [12] and is shown in Fig. lb. The hammerhead ri- 
bozyme reported here has been designed to cleave both A- 
SAA1 and A-SAA2 mRNA; as a result of the high degree of 
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Fig. 2. Magnesium-dependent cleavage of A-SAA mRNA by RzSAA 
in vitro. In vitro transcribed A-SAA2 mRNA (555 bases) and RzSAA 
ribozyme (derived from RpSAA) were incubated for 4 h with 50 mM 
Tris-HCl and increasing concentrations of MgC12 (indicated along the 
top of each lane). The sizes of the A-SAA2 cleavage fragments (433 and 
122 bases) are indicated. Note the absence of cleavage fragments inlane 
1, due to the absence of MgCI 2. 
sequence homology between both genes, the target sequence 
flanking the GUX at 107 109 is identical in both. This will 
allow for the eventual targetting of both acute-phase mRNAs 
in cell culture and in vivo studies in which both species will be 
present. 
The in vitro cleavage reactions were carried out using target 
A-SAA2 mRNA, which is full-length (542 bases plus 13 bases 
of vector derived sequence at the 5' end), and therefore likely 
to fold into the most authentic representation f the A-SAA2 
mRNA secondary structure found in vivo. Incubation of in 
vitro transcribed A-SAA2 mRNA and ribozyme resulted in 
magnesium-dependent cl avage of the A-SAA2 mRNA to the 
expected fragments of 122 (109 bases of A-SAA2 mRNA plus 
13 vector-derived bases) and 433 bases (Fig. 2). The magnesium 
dependence of the ribozyme cleavage reaction is in concor- 
dance with previous observations that such hammerhead cleav- 
age reactions have an absolute requirement for divalent metal 
ions [18]. 
The activity of a ribozyme also depends on the in vivo stabil- 
ity of the ribozyme. The poly(A) tail and 5' cap structure both 
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Fig. 3. Autocatalytic assette for the generation of anti-A-SAA ribozymes with defined 3'-termini. (a) The autocatalytic cassette used to generate 
an anti-A-SAA ribozyme with a defined 3'-terminus (RzSAA3"). The second, autocatalytic, ribozyme (Rz3') forms a hammerhead structure (details 
in text) and cleaves the A-SAA ribozyme at the 3' end at the position indicated. (b) In vitro transcription from the autocatalytic cassette: lane 1 = size 
markers; lane 2 = product following transcription of RzSAA3'. The a utocatalytic cassette has completely self-cleaved into the expected size fragements 
(61 and 47 bases). Note the additional bands at 46 and 48 bases which are extraneous cleaved transcription products due to transcription from a 
template with a 3' overhang (the template was linearised with Apal prior to transcription). (c) A-SAA2 mRNA incubated with RzSAA transcribed 
directly from RpSAA (lane 1) and the gel purified 5' fragment released by the autocatalytyic cleavage of RzSAA3' (lane 2). The expected A-SAA2 
mRNA cleavage products are present in lane 2, indicating that the 5' fragment generated from the autocatalytic ribozyme is a functional anti-A-SAA 
ribozyme. 
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play a well-documented role in the stability of many eukaryotic 
mRNAs [19,20]. Due to the presence of polyadenylation signal 
sequences and a poly(A) tail at the 3' end, the A-SAA ribozyme 
(RzSAA) transcribed in vivo will be 200-300 bases larger than 
the 60 base ribozyme produced in vitro. This increase in size 
may, however, prevent access of the ribozyme to the target site. 
cis-Cleaving autocatalytic ribozymes have been previously used 
to generate RNA transcripts with defined 5'- and 3'-termini 
[21,22]. We have therefore designed an autocatalytic cassette 
(RpSAA3') that contains RzSAA immediately upstream of an- 
other ribozyme and is capable of folding back and forming a 
hammerhead ribozyme using the 3' end of RzSAA as the target 
substrate and cleaving between the two (Fig. 3a). The resulting 
ribozyme generated from this construct (RzSAA3') will have a 
defined 3' end lacking a poly(A) tail and thus is likely to more 
efficiently access the target site on A-SAA mRNA. This au- 
tocatalytic cassette, tested in vitro, self-cleaves completely dur- 
ing transcription toproduce two fragments; the 61 base RzSAA 
and the 47-base 3' ribozyme (Fig. 3b). The 61-base fragment 
was gel purified and shown to cleave A-SAA2 mRNA into the 
expected fragment sizes, thus indicating that it is a fully func- 
tional anti-A-SAA ribozyme (Fig. 3c). It will be possible to 
transcribe ach of the above anti-A-SAA ribozymes in vivo 
with the guanosine cap structure at the 5' end which will protect 
the ribozyme from 5' to 3' exonucleotic degradation. 
The aim of this in vitro study was to design and test a 
functional anti-A-SAA ribozyme which can be adapted for 
future in vivo studies of the applicability of ribozyme technol- 
ogy to the specific down-regulation f A-SAA synthesis under 
pro-inflammatory conditions. We have successfully generated 
a hammerhead ribozyme that cleaves full-length A-SAA 
mRNA in vitro in a magnesium-dependent, pro ein-independ- 
ent manner. A second cis-cleaving ribozyme, when positioned 
downstream from the A-SAA ribozyme, has been shown to be 
fully active in vitro, releasing a functional 61-base anti-A-SAA 
ribozyme; this 61-base ribozyme is considerably smaller than 
the polyadenylated A-SAA ribozyme that would be synthesised 
by the 'basic' ribozyme. As a result his ribozyme may be able 
to target he substrate more efficiently and may prove to be a 
more effective catalyst in vivo. 
The ultimate goal of this work is to achieve anti-A-SAA 
ribozyme mediated own-regulation f A-SAA synthesis in a 
transgenic animal carrying ahuman A-SAA transgene. In addi- 
tion to the use of such an experimental model to determine the 
general effectiveness of ribozymes as therapeutic agents under 
inflammatory conditions, it could also be used as a model to 
obtain information regarding the 'normal' protective function 
of the A-SAAs during the acute phase response, the pathogenic 
consequences of chronic concentrations of A-SAA, and the 
therapeutic potential of anti-A-SAA ribozymes in the treatment 
of A-SAA dependent diseases uch as secondary amyloidosis 
and possibly atherosclerosis. 
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